Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEPW) EBITDA Margin (2021 - 2025)

Coeptis Therapeutics Holdings has reported EBITDA Margin over the past 2 years, most recently at 230.64% for Q4 2025.

  • Quarterly results put EBITDA Margin at 230.64% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 956.94% (changed N/A YoY), and the annual figure for FY2025 was 956.94%, changed.
  • EBITDA Margin for Q4 2025 was 230.64% at Coeptis Therapeutics Holdings, up from 1043.22% in the prior quarter.
  • Over the last five years, EBITDA Margin for COEPW hit a ceiling of 86.15% in Q4 2021 and a floor of 6452.56% in Q1 2025.